… III RELAY study have demonstrated superior PFS with erlotinib … the inclusion of patients with
stable brain metastases whereas … half the patients treated with erlotinib plus ramucirumab. …

… trial in China, a double-blind, head-to-head phase III study … T790M mutation-positive
advanced NSCLC patients treated with … Ramucirumab in combination with erlotinib significantly …

… patients, have demonstrated PFS benefit of erlotinib plus … On the other side, treatment of
osimertinib plus ramucirumab … This has been observed in the NEJ 026 and RELAY studies in …

… to daily erlotinib with ramucirumab, or erlotinib with placebo. … for the treatment of patients
with locally advanced, metastatic or … combination with erlotinib alone in EGFR mutation positive …

… They were ranked the top two treatments for patients with brain metastasis. Better … erlotinib
and ramucirumab showed a significantly improved PFS of 19.4 months in the RELAY trial…

… This was a retrospective, multicenter cohort study of patients … patients with baseline brain
metastases no longer had brain … , such as erlotinib plus either ramucirumab or bevacizumab, …

… of treatment of metastatic NSCLC, as well small-cell lung … received either nivolumab or
placebo and the median OS was … Ramucirumab in combination with erlotinib showed a slightly …

… in 16% of patients versus 13% in the placebo group (16). … such as erlotinib plus ramucirumab
or erlotinib plus bevacizumab have … II multicenter study has analyzed toxicity in 381 patients …

… 3 RELAY trial was designed to compare ramucirumab plus erlotinib and erlotinib alone and
ramucirumab plus erlotinib showed superior PFS in patients with EGFR-mutated metastatic …

… plus ramucirumab versus erlotinib plus placebo 19 … with BRAF V600 mutation–positive NSCLC,
the primary outcome, … or metastatic tumors who had previous treatment with therapy other …